Public-registry trials using Safusidenib that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease | Nuvation Bio Inc. | Grade 2 IDH1-mutant Glioma | PHASE2 | 0 |
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →